Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present AIT Therapeutics, Inc. (OTC: AITB).

Full DD Report for AITB

Recent News from (OTC: AITB)

AIT Therapeutics Names Stephen J. DiPalma as Chief Financial Officer
Industry veteran brings over 30 years of experience to AIT NEW YORK, April 16, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with re...
Source: GlobeNewswire
Date: April, 16 2018 08:30
AIT Granted New Patent for Its Nitric Oxide (NO) Generator and Delivery System
Patent covers technology for a disposable that filters nitrogen dioxide (NO2) gas and programs the system for use NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) --  AIT Therapeutics, Inc. (OTC:AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inh...
Source: GlobeNewswire
Date: March, 29 2018 08:30
AIT Therapeutics reports FY results
AIT Therapeutics ( OTCPK:AITB ): FY EPS of -$3.01 Press Release More news on: AIT Therapeutics, Inc., Earnings news and commentary, Tech stocks news, ,
Source: SeekingAlpha
Date: March, 19 2018 16:19
AIT Therapeutics Reports Year End 2017 Financial Results
Expects first regulatory filing for the NO Generator and Delivery System in persistent pulmonary hypertension of the newborn (PPHN) by end of 2018 Closed global, exclusive license for revolutionary NO Generator and Delivery System Reported positive data in 9 cystic fibrosis (CF) p...
Source: GlobeNewswire
Date: March, 19 2018 16:01
Key events next week - healthcare
Noteworthy events for the week of March 18 - 24 for healthcare investors: More news on: Spark Therapeutics, SELLAS Life Sciences Group, Inc., Atara Biotherapeutics, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: March, 16 2018 10:25
AIT Therapeutics Announces Year End 2017 Financial Results Conference Call and Webcast
Call Scheduled for Monday, March 19, 2018 at 4:30pm Eastern Time. NEW YORK, March 13, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung in...
Source: GlobeNewswire
Date: March, 13 2018 08:00
AIT Therapeutics to Present at Two Investor Conferences
REHOVOT, Israel and NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announce...
Source: GlobeNewswire
Date: March, 07 2018 16:05
AIT Therapeutics Appoints Two Senior Executives in Research and Clinical Operations
Mark Rimkus Appointed VP of Clinical Affairs and Dr. Abdi Ghaffari Appointed VP of Research Appointments Add Decades of Nitric Oxide Experience to Team NEW YORK, Feb. 20, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused o...
Source: GlobeNewswire
Date: February, 20 2018 16:30
AIT Therapeutics Announces $9.82 Million Private Placement
NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that it has complet...
Source: GlobeNewswire
Date: February, 16 2018 11:02
AIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery System
First Regulatory Filing for the eNOGenerator System Expected By End of 2018 NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious...
Source: GlobeNewswire
Date: January, 31 2018 16:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-193.003.003.003.004,450
2018-04-182.953.003.002.805,300
2018-04-172.803.003.002.80400
2018-04-162.853.003.002.85700
2018-04-153.003.003.003.00900

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-04-189005,30016.9811Cover
2018-04-1310090011.1111Cover
2018-04-1214,30020,50069.7561Short
2018-04-118,02322,20036.1396Short
2018-04-094,7009,07551.7906Short

* Short Mode

Short Analysis provided by Squeeze Report.


About AIT Therapeutics, Inc. (OTC: AITB)

Logo for AIT Therapeutics, Inc. (OTC: AITB)

Not available

 

Contact Information

 

 

Current Management

  • Steven A. Lisi / CEO
  • Amir Avniel / President, COO
  • Hai Aviv / CFO
    • Mr. Aviv, who is years old, will join the Company from Babylon Ltd., a publiclytraded Israeli company listed on the Tel Aviv Stock Exchange, operating in the fields of Internet, risk capital investments and software, where he has served as Chief Financial Officer from to the present. From to , Mr. Aviv served as Babylon s corporate controller. Mr. Aviv is a certified public accountant and, from to , served as manager at the Ernst amp Young Accounting Firm, Kost Forer, Gabbay amp Kasierer, working predominantly with the hightech team.
  • Amir Avniel /
  • Steven A. Lisi /

Current Share Structure

  • Market Cap: $18,230,789 - 03/20/2018
  • Issue and Outstanding: 6,097,254 - 11/01/2017

 


Recent Filings from (OTC: AITB)

Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 02 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 30 2018
Amendment to general form for registration of securities under the Securities Act of 1933
Filing Type: S-1/AFiling Source: edgar
Filing Date: March, 29 2018
General form for registration of securities under the Securities Act of 1933
Filing Type: S-1Filing Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 22 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: March, 09 2018
Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
Filing Type: DFiling Source: edgar
Filing Date: March, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 22 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: February, 22 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: February, 22 2018

 

 


Daily Technical Chart for (OTC: AITB)

Daily Technical Chart for (OTC: AITB)


Stay tuned for daily updates and more on (OTC: AITB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AITB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

Monsta Trader
@MonstaTrader

 

 


Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AITB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of AITB and does not buy, sell, or trade any shares of AITB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us